Acute Promyelocytic Leukemia

We validated these clinical and molecular findings in an independent validation cohort of 302 NPM1 mut patients enrolled in the acute myeloid leukemia study group (AMLSG) 09-09 clinical trial, which included the administration of all-trans retinoic acid (ATRA) to all patients and a randomization for gemtuzumab ozogamicin. In this cohort, the APL-like immunophenotype was associated with events occurring within the first 15 days but did not influence mortality, likely due to protocol-driven patient selection. Our findings have important clinical implications that warrant the development of studies exploring disease-tailored clinical measures to mitigate the risk of early vascular events, as in current APL management.

P1, N=77, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting

Both agents mitigate ATO‑induced neurotoxicity through antioxidant, anti‑inflammatory, and anti‑apoptotic mechanisms, with their co‑administration surpassing individual efficacy. The Keap‑1/Nrf2/HO‑1 axis emerges as a critical therapeutic node, underscoring the translational potential of combined intervention.

CRLM patients exhibit distinct serum metabolic profiles, among which high-abundance TCA can induce NET release and thereby promote CRC cell metastasis. This process is associated with the activation of the p44/42 MAPK/mTOR signaling pathways in neutrophils and the epithelial-mesenchymal transition in CRC cells.

Multidisciplinary supportive care with continuation of ATRA-ATO therapy resulted in complete hematologic and molecular remission. This case highlights the importance of recognizing and managing complex complications in APL while maintaining curative therapy.

Not available.

P3, N=150, Recruiting, Quetzal Therapeutics

P3, N=224, Recruiting, First Affiliated Hospital Xi'an Jiaotong University

When interpreted together with the in silico analyses performed on AML patient datasets, these results support the rationale for future validation in APL-oriented models carrying the PML::RARα fusion, the disease-defining oncogenic driver generated by the t(15;17) translocation that blocks myeloid differentiation. However, the in silico and in vitro datasets were not formally integrated at the patient level, and these functional results should be considered exploratory.

Despite prompt initiation of all-trans retinoic acid and arsenic trioxide therapy, she developed worsening respiratory distress and neurological deterioration, succumbing within 70 hours of admission...The optimal management strategies remain undefined, particularly for CNS-directed therapy. This case underscores the importance of considering extramedullary involvement in APL patients with atypical or rapidly progressive presentations.

This study demonstrated that piperine at 20 mg/kg orally was protective in arsenic trioxide-induced cardiotoxicity in an experimental rat model. This study is the first to combine serum biomarkers and ECG analysis to demonstrate piperine's cardioprotective role. It may have clinical relevance in exploring the potential of piperine to reduce arsenic trioxide-induced cardiotoxicity.